文献速递神经肿瘤脑血管病外科神经重症

接受贝伐珠单抗治疗的高级别胶质瘤患者血栓栓塞与出血事件的风险与负担

The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab.
PubMed 文献 · J Neurooncol · 2024-02-19

该多机构回顾性研究评估高级别胶质瘤患者接受贝伐珠单抗治疗后静脉血栓栓塞(VTE)和颅内出血(ICH)的临床危险因素。研究发现MRI上磁敏感体积>1 cm³的脑macrobleeding与贝伐珠单抗启动后ICH风险高度相关,且ICH与更差生存显著相关;VTE对生存无统计学显著影响。作者建议在贝伐珠单抗启动前评估脑macrobleeding以分层ICH风险。

要点

  • 脑macrobleeding(MRI磁敏感>1 cm³)与贝伐珠单抗启动后ICH风险高度相关。
  • 贝伐珠单抗启动后发生ICH与更差生存结局显著相关。
  • VTE对贝伐珠单抗启动后生存无统计学显著影响。

核心结论

  • 作者建议在贝伐珠单抗启动前评估脑macrobleeding以分层ICH发生风险,因其与ICH发展相关。
  • ICH发生与更差生存结局显著相关,VTE对贝伐珠单抗启动后生存无统计学显著影响。

研究设计与样本

  • 多机构回顾性研究,首先评估2015-2021年德克萨斯大学MD安德森癌症中心接受贝伐珠单抗治疗的高级别胶质瘤患者。
  • 比较发生VTE、ICH或两者均无的三个队列的临床与治疗相关因素,并从贝伐珠单抗启动时比较生存结局。
  • 进一步在非癌症中心医院环境中评估2017-2022年德克萨斯州奥斯汀两家Ascension Seton医院(隶属德克萨斯大学奥斯汀分校Dell医学院)的患者以确认结果。

主要发现

  • 脑macrobleeding(MRI磁敏感>1 cm³)与贝伐珠单抗启动后ICH风险高度相关。
  • ICH发生与更差生存结局显著相关。
  • VTE对贝伐珠单抗启动后生存无统计学显著影响。

关键数值与推荐

  • 脑macrobleeding定义为MRI上磁敏感>1 cm³。

临床怎么用

  • 作者建议在贝伐珠单抗启动前评估脑macrobleeding以分层ICH发生风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bevacizumab has evolved as an integral treatment option for patients with high-grade gliomas. Little is known about clinical risk factors that predispose patients with high-grade gliomas receiving bevacizumab to VTE or ICH. We sought to characterize the clinical risk factors associated with risk of either event. METHODS: In this multi-institutional retrospective study, we first evaluated patients with high-grade gliomas who were treated with bevacizumab at University of Texas MD Anderson Cancer Center from 2015-2021. We compared clinical and treatment-related factors among three cohorts: those who developed VTE, ICH, or neither. We further compared survival outcomes of these patients from the time of bevacizumab initiation. Then to further confirm our results in a non-cancer center hospital setting we evaluated patients from two Ascension Seton Hospitals in Austin, Texas which are affiliated with Dell Medical School at the University of Texas at Austin from 2017-2022. RESULTS: We found that the presence of cerebral macrobleeding, defined as a magnetic susceptibility of > 1 cm3 on magnetic resonance imaging, was highly associated with risk of developing ICH after initiation of bevacizumab. Development of ICH was significantly associated with poorer survival outcomes. We did not find a statistically significant effect of VTE on survival after bevacizumab initiation. CONCLUSION: In order to stratify the risk for developing ICH before the initiation of bevacizumab, we recommend to assess for the presence of cerebral macrobleeding as it is associated with ICH development.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dasgupta P, Ou A, Lin H, et al. The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. J Neurooncol. 2024. PMID: 38372903. doi:10.1007/s11060-023-04551-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。